

Hepatitis B virus and host factors

Yoshihiko Yano^{1,2}, Yasushi Seo², Takeshi Azuma², Yoshitake Hayashi¹

¹Center for Infectious Diseases and ²Department of Gastroenterology, Kobe University Graduate School of Medicine, Japan

Corresponding to: Yoshihiko Yano, MD, PhD. Center for Infectious Diseases and Department of Gastroenterology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. Email: yanoyo@med.kobe-u.ac.jp.



Submitted Sep 22, 2012. Accepted for publication Oct 22, 2012.

doi: 10.3978/j.issn.2304-3881.2012.10.10

Scan to your mobile device or view this article at: <http://www.thehbsn.org/article/view/1167/1855>

Primary liver cancer is the third most common cause of cancer-related deaths worldwide, with a particularly high incidence in Asian countries. Hepatocellular carcinoma (HCC) accounts for 85-90% of primary liver cancers, and is responsible for approximately 660,000 deaths worldwide each year (1). Hepatitis B virus (HBV) is the most common cause of infectious liver diseases. About 400 million people suffer from chronic HBV infection worldwide, and approximately 60% of HCC cases each year are related to chronic HBV infection (2). It has been suggested that viral factors (e.g., HBV-DNA levels, genotypes, and genomic mutations), host factors (e.g., age, sex, race, and immune status), and unhealthy lifestyles might contribute to the progression of liver diseases (3).

Hepatocarcinogenesis is a multi-factorial process in which genetic and epigenetic factors contribute to abnormal activation or inactivation of multiple cellular signaling pathways that result in malignant transformation (4). Integration of HBV into the host's genome and transactivation of HBx protein promotes and enhances multiple cellular signaling genes (5). For example, this process activates oncogenic genes (e.g., c-myc and c-fos), inactivates suppressor genes (e.g., p53), activates transcriptional factors (e.g., AP-1 and NF- κ B), and induces the loss of heterozygosity.

Recent technological advances have revealed that several genetic factors are associated with cancers. Genome-wide association studies (GWAS) have identified numerous single nucleotide polymorphisms (SNPs) that are associated with various cancers. With respect to liver cancers, SNPs in numerous candidate genes were reported to be associated with HCC in case-control and retrospective studies. *Table 1* summarizes the results of GWAS identifying genetic factors implicated in HCC. In 2009, Kamatani *et al.* first reported that SNPs in the human leukocyte antigen (HLA)-DP region

were associated with chronic HBV in a study of 188 Japanese patients with chronic HBV infection and 934 controls (6). The HLA gene is located in the region 6p21.3 and plays an important role in antigen presentation. Polymorphisms in this region were also reported in Chinese patients (8,12). In 2010, Zhang *et al.* reported that SNPs in several tumor suppressor genes located in the region 1p36.22, including KIF1B, UBE4B, and PGD, were putatively associated with HCC (7). However, no data from other countries in Asia, or globally, have been published to confirm these associations. GWAS may result in some discrepancies because of differences among ethnicities. Most of the studies published to date were conducted in Asian countries, particularly China and Japan (*Table 1*). Therefore, it is necessary to confirm these associations in other countries and ethnicities.

It is also important that such studies include samples from patients and controls. Several studies identified candidate SNPs by comparing the SNPs present in asymptomatic HBV carriers and HCC patients. However, other factors, including age, sex, viral load, and viral mutations, are often clinically very different between these two groups, and may confound the analyses. Therefore, to precisely analyze genetic factors, it is essential that the patients and controls are well matched for these factors to limit possible confounding. Several studies have also enrolled patients with chronic HBV infection and controls without HBV infection. The results of these studies imply that several SNPs are associated with persistent infection and HBV clearance. Functional analyses are necessary to confirm these results.

Chronic hepatitis B (CHB) normally progresses through five phases: immune tolerance, immune clearance, inactive carrier, reactivation, and recovery. However, the duration and underlying hepatitis disease activity vary considerably

Table 1 SNPs associated with chronic HBV infection and HBV-related HCC						
Chr	SNP region	rs./region	Ethnicity	Cases/Control	OR	Reference
6p	HLA-DPA1 HLA-DPB1	rs3077 rs9277535	Japanese	786 CHB /2201 controls	1.45-2.31	Kamatani 2009 (6)
1p	UBE4B-KIF1B-PGD	rs17401966	Asian	1962 HBV-HCC/1430 CHB	1.63	Zhang 2010 (7)
6p	HLA-DP		Han Chinese	521 CHB/819 control	1.98	Guo 2011 (8)
6p	HLA-DPA1 HLA-DBB1	rs3077 rs9277535	European	651 liver tissue samples/ Ref. (6)		O'Brien 2011 (9)
6p	HLA-DPA1 HLA-DPB1 HLA-DQB1 HLA-DQB2	rs3077 rs9277535 rs2856718 rs7453920	Japanese	458 CHB/2056 controls	1.98 1.95 1.59 2.20	Mbarek 2011 (10)
16p	GRIN2A	rs11866328	Chinese	1944 progressed carriers/ 854 asymptomatic carriers	1.65-1.73	Liu 2011 (11)
6p	HLA-DPA1 HLA-DPB1 HLA-DQB1 HLA-DQB2	rs3077 rs9277535 rs2856718 rs7453920	Chinese	1300 HCC/ 1344 CHB/ 1344 controls with natural clearance	0.29-1.89	Hu 2012 (12)
8p	DLC1	rs12682266 rs7821974 rs2275959 rs1573266	Chinese	95 HBV-HCC/ 97 HCC without HBV	1.38 1.33 1.31 1.39	Chan 2011 (13)
6p	HLA-DPB1	rs9277535 rs9277534	European-American African-American	241 CHB/ 421 recovered from HBV	0.39 0.37	Thomas 2012 (14)
1p	KIF1B	rs8019 rs17401924 rs17401966	Chinese	473 CHB/ 580 controls	No association	Zhong 2012 (15)
1p	KIF1B	rs17401966	Japanese, Korean, Chi- nese	580 HBV-HCC/ 1351 CHB	No association	Sawai 2012 (16)
6p	HLA-DPA1 HLA-DPB1	rs3077 rs9277542	Japanese, Korean, Chinese, Thai	181 CHB/ 184 controls	0.42 0.42	Nishida 2012 (17)
6p 21q	HLADQA1/DRB1 GRIK1	rs9272105 rs455804	Chinese	1538 HBV-HCC/ 1465 CHB	1.30 1.86	Li 2012 (18)
1p	KIF1B	rs17401966 rs12734551 rs3748578	Saudi Arabian	660 CHB/ 584 controls	No association	Al-Qahtani 2012 (19)

between each phase. Additionally, the clinical course differs between patients. HBV itself is not usually cytopathogenic. Instead, the liver injuries in patients with chronic HBV infection are considered to be the result of the host's immune responses against HBV. For example, an HLA-class I antigen-restricted, cytotoxic T lymphocyte-mediated response to the HBV antigen expressed on hepatocytes results in apoptosis and necrosis (20). Viral and host factors are associated with viral clearance, persistent infection, and clinical course. It was reported that HLA-DP variants were associated with chronic persistent hepatitis following HBV infection. The HLA-DP molecule plays an important role in antigen presentation to cytotoxic T cells. Therefore, functional differences in HLA-DP might contribute to differences in host sensitivity to the virus.

Li *et al.* identified a susceptibility gene within the HLA region, and the SNP identified in their study may influence HLA function. GWAS provide abundant information on a variety of diseases (18). However, the generalizability of the results should still be discussed because the data may differ according to ethnicity and other confounding factors. The pathogenesis of HCC involves multifactorial processes. Further studies are needed to determine whether the susceptibility gene reported by Li *et al.* shows clinical generalizability, and to determine the importance of this gene in the progression of HCC.

Acknowledgements

Disclosure: The authors declare no conflict of interest.

References

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology* 2007;132:2557-76.
2. Lai CL, Ratziu V, Yuen MF, et al. Viral hepatitis B. *Lancet* 2003;362:2089-94.
3. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. *Liver Int* 2009;29:100-7.
4. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. *Semin Liver Dis* 2010;30:3-16.
5. Paterlini-Br  chot P, Saigo K, Murakami Y, et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. *Oncogene* 2003;22:3911-6.
6. Kamatani Y, Watanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. *Nat Genet* 2009;41:591-5.
7. Zhang H, Zhai Y, Hu Z, et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. *Nat Genet* 2010;42:755-8.
8. Guo X, Zhang Y, Li J, et al. Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population. *Hepatology* 2011;53:422-8.
9. O'Brien TR, Kohaar I, Pfeiffer RM, et al. Risk alleles for chronic hepatitis B are associated with decreased mRNA expression of HLA-DPA1 and HLA-DPB1 in normal human liver. *Genes Immun* 2011;12:428-33.
10. Mbarek H, Ochi H, Urabe Y, et al. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. *Hum Mol Genet* 2011;20:3884-92.
11. Liu L, Li J, Yao J, et al. A genome-wide association study with DNA pooling identifies the variant rs11866328 in the GRIN2A gene that affects disease progression of chronic HBV infection. *Viral Immunol* 2011;24:397-402.
12. Hu L, Zhai X, Liu J, et al. Genetic variants in human leukocyte antigen/DP-DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development. *Hepatology* 2012;55:1426-31.
13. Chan KY, Wong CM, Kwan JS, et al. Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection. *PLoS One* 2011;6:e28798.
14. Thomas R, Thio CL, Apps R, et al. A novel variant marking HLA-DP expression levels predicts recovery from hepatitis B virus infection. *J Virol* 2012;86:6979-85.
15. Zhong R, Tian Y, Liu L, et al. HBV-related hepatocellular carcinoma susceptibility gene KIF1B is not associated with development of chronic hepatitis B. *PLoS One* 2012;7:e28839.
16. Sawai H, Nishida N, Mbarek H, et al. No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations. *BMC Med Genet* 2012;13:47.
17. Nishida N, Sawai H, Matsuura K, et al. Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. *PLoS One* 2012;7:e39175.
18. Li S, Qian J, Yang Y, et al. GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers. *PLoS Genet* 2012;8:e1002791.
19. Al-Qahtani A, Al-Anazi M, Viswan NA, et al. Role of Single Nucleotide Polymorphisms of KIF1B Gene in HBV-Associated Viral Hepatitis. *PLoS One* 2012;7:e45128.
20. Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. *J Gastroenterol Hepatol* 2003;18:246-52.

Cite this article as: Yano Y, Seo Y, Azuma T, Hayashi Y. Hepatitis B virus and host factors. *Hepatobiliary Surg Nutr* 2013;2(2):121-123. doi: 10.3978/j.issn.2304-3881.2012.10.10